These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30418552)

  • 1. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
    McQuillen DP; Ram S
    Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
    [No Abstract]   [Full Text] [Related]  

  • 2. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria.
    Benz R; Krause M; Majer S; Taverna C; Herzog K
    Br J Haematol; 2018 Aug; 182(3):318. PubMed ID: 29676447
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 4. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Lee JW; Kulasekararaj AG
    Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
    [No Abstract]   [Full Text] [Related]  

  • 6. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
    Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
    Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab in pregnancy: a narrative overview.
    Sarno L; Tufano A; Maruotti GM; Martinelli P; Balletta MM; Russo D
    J Nephrol; 2019 Feb; 32(1):17-25. PubMed ID: 30159857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
    Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
    Zhou S; Dong X; Chen C; Ma L; Wu Y; Zhou Y; Cui Y
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):203-210. PubMed ID: 33902068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
    Lee SE; Lee JW
    Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
    [No Abstract]   [Full Text] [Related]  

  • 12. Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine.
    Yu ZY; Tsai MJ; Lin YJ; Liu WD; Chou SC; Hung CC
    J Microbiol Immunol Infect; 2020 Aug; 53(4):660-662. PubMed ID: 32624359
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
    Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
    Front Immunol; 2019; 10():1639. PubMed ID: 31379839
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
    Scheinberg P; Clé DV; Kim JS; Nur E; Yenerel MN; Barcellini W; Bonito D; Giai V; Hus M; Lee Y; Lekue CB; Panse J; Ueda Y; Buatois S; Gentile B; Kiialainen A; Patel H; Sreckovic S; Uguen M; Edwards J; Nagy Z; Kulasekararaj AG
    Am J Hematol; 2024 Sep; 99(9):1757-1767. PubMed ID: 38924124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 17. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series.
    Crew PE; Abara WE; McCulley L; Waldron PE; Kirkcaldy RD; Weston EJ; Bernstein KT; Jones SC; Bersoff-Matcha SJ
    Clin Infect Dis; 2019 Aug; 69(4):596-600. PubMed ID: 30418536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
    Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
    Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.